Mylan Launches First Generic Klor-Con ER Tablets

(RTTNews) - Mylan Inc. (MYL) said Friday that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq and 10 mEq, which is the generic version of Upsher-Smith's Klor-Con.

Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for the product, which is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis.

Mylan has begun shipping the product.

Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), had U.S. sales of about $135.05 million for the 12 months ending June 30, 2014, according to IMS Health.